Detalhe da pesquisa
1.
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
N Engl J Med
; 390(17): 1560-1571, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587254
2.
Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years.
N Engl J Med
; 389(21): 1949-1960, 2023 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37874020
3.
Polypill Strategy in Secondary Cardiovascular Prevention.
N Engl J Med
; 387(11): 967-977, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36018037
4.
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
Circulation
; 148(13): 1011-1022, 2023 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37621153
5.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
N Engl J Med
; 385(16): 1451-1461, 2021 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34449189
6.
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Eur Heart J
; 44(5): 396-407, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36478225
7.
Socioeconomic Deprivation: An Important, Largely Unrecognized Risk Factor in Primary Prevention of Cardiovascular Disease.
Circulation
; 146(3): 240-248, 2022 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35748241
8.
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
Circulation
; 146(9): 676-686, 2022 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35762322
9.
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Circulation
; 145(3): 184-193, 2022 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779658
10.
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
Circulation
; 146(14): 1046-1055, 2022 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36098051
11.
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
N Engl J Med
; 383(15): 1413-1424, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32865377
12.
Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registry.
Am Heart J
; 263: 26-34, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37094668
13.
Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation.
Am Heart J
; 264: 123-132, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279840
14.
Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction - insights from the IAMI trial.
Am Heart J
; 255: 82-89, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36279930
15.
Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial.
J Card Fail
; 29(10): 1345-1354, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37558088
16.
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
Eur Heart J
; 43(5): 416-426, 2022 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34878502
17.
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
Eur Heart J
; 43(31): 2984-2993, 2022 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35687107
18.
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Eur Heart J
; 43(36): 3435-3446, 2022 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788657
19.
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme.
Eur Heart J
; 43(48): 4991-5002, 2022 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36017745
20.
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.
Eur Heart J
; 43(7): e17-e25, 2022 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31270529